

Cyclo Therapeutics, Inc. – The New Name for CTD Holdings.

ALACHUA, FL–(Businesswire) – 04 October 2019 – Cyclo Therapeutics, Inc. (OTCQB: CTDH) announced today that it has completed its name change from CTD Holdings, Inc. following appropriate regulatory filings with the State of Florida and FINRA. The new name better reflects the company’s business as a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, most notably Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company will continue to trade on the OTCQB Exchange under the symbol CTDH. The new name was overwhelmingly approved by shareholders at their meeting on August 27th.

“As we continue to develop our clinical programs in disease areas that can be potentially treated with Trappsol® Cyclo™, the Cyclo Therapeutics, Inc. name better reflects the Company’s main business going forward. We look forward to continued progress and higher recognition of our important biopharmaceutical products,” said Company Chairman & CEO, N. Scott Fine.

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical Trials.gov [NCT02939547](#), [NCT02912793](#) and [NCT03893071](#)) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com

Safe Harbor Statement:

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not

limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Investor/Media Contact:

RedChip Companies, Inc.
Victor Roberts
407-571-0909
victor@redchip.com